The use of prophylactic eye drops during high‐dose cytosine arabinoside therapy

32Citations
Citations of this article
19Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

An ocular toxic reaction presenting as conjunctivitis or keratitis develops in a significant number of patients who are treated with high‐dose cytosine arabinoside (ara‐C). Although eye drops containing glucocorticoid reportedly decrease the incidence, they do not totally eliminate this side effect. In comparing this technique with artificial tears, both were found to be equally effective. The primary mechanism by which eye drops decrease ocular toxic reactions associated with high‐dose ara‐C is presumably due to dilution of intraocular concentrations of ara‐C. Copyright © 1991 American Cancer Society

Cite

CITATION STYLE

APA

Higa, G. M., Gockerman, J. P., Hunt, A. L., Jones, M. R., & Horne, B. J. (1991). The use of prophylactic eye drops during high‐dose cytosine arabinoside therapy. Cancer, 68(8), 1691–1693. https://doi.org/10.1002/1097-0142(19911015)68:8<1691::AID-CNCR2820680805>3.0.CO;2-W

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free